L & S Advisors Inc Biomarin Pharmaceutical Inc Transaction History

L & S Advisors Inc

  • $771 Million
  • Q2 2024

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 10, 2023
SELL
$87.74 - $117.27 $359,295 - $480,220
-4,095 Reduced 32.22%
8,616 $837,000
Q4 2022

Feb 13, 2023
BUY
$80.93 - $108.63 $269,577 - $361,846
3,331 Added 35.51%
12,711 $1.32 Million
Q3 2022

Nov 14, 2022
BUY
$82.16 - $96.94 $770,660 - $909,297
9,380 New
9,380 $795,000
Q3 2020

Nov 13, 2020
SELL
$71.87 - $131.03 $636,696 - $1.16 Million
-8,859 Closed
0 $0
Q2 2020

Aug 13, 2020
BUY
$79.55 - $124.22 $33,331 - $52,048
419 Added 4.96%
8,859 $1.09 Million
Q1 2020

May 13, 2020
SELL
$71.37 - $96.85 $8,921 - $12,106
-125 Reduced 1.46%
8,440 $713,000
Q4 2019

Feb 13, 2020
BUY
$64.27 - $86.37 $93,191 - $125,236
1,450 Added 20.38%
8,565 $724,000
Q3 2019

Nov 14, 2019
SELL
$67.4 - $85.11 $208,872 - $263,755
-3,099 Reduced 30.34%
7,115 $480,000
Q2 2019

Aug 13, 2019
BUY
$80.35 - $93.9 $58,575 - $68,453
729 Added 7.69%
10,214 $875,000
Q1 2019

May 14, 2019
BUY
$84.2 - $98.62 $142,298 - $166,667
1,690 Added 21.68%
9,485 $843,000
Q4 2018

Feb 14, 2019
SELL
$80.14 - $106.07 $62,909 - $83,264
-785 Reduced 9.15%
7,795 $664,000
Q3 2018

Nov 14, 2018
BUY
$93.92 - $105.72 $152,620 - $171,795
1,625 Added 23.36%
8,580 $832,000
Q2 2018

Aug 13, 2018
BUY
$76.01 - $99.03 $528,649 - $688,753
6,955 New
6,955 $655,000

Others Institutions Holding BMRN

# of Institutions
632
Shares Held
185M
Call Options Held
1.63M
Put Options Held
1.2M
View Full List

About BIOMARIN PHARMACEUTICAL INC

BMRN Quotes by TradingView
  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $13.1B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track L & S Advisors Inc Portfolio

Follow L & S Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of L & S Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on L & S Advisors Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email